Kane Biotech Inc. (KNE.V)
- Previous Close
0.1350 - Open
0.1400 - Bid 0.1350 x --
- Ask 0.1450 x --
- Day's Range
0.1400 - 0.1400 - 52 Week Range
0.0500 - 0.1700 - Volume
5,000 - Avg. Volume
182,001 - Market Cap (intraday)
18.458M - Beta (5Y Monthly) 0.55
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date May 23, 2024 - May 27, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; and animal and human wound care solutions under the DispersinB name. It also offers scalp care products under the DermaKB brand name; and wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, Aledex, and DermaKB Biofilm brand names. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.
kanebiotech.comRecent News: KNE.V
Performance Overview: KNE.V
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KNE.V
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KNE.V
Valuation Measures
Market Cap
18.46M
Enterprise Value
26.96M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
119.46
Price/Book (mrq)
--
Enterprise Value/Revenue
180.97
Enterprise Value/EBITDA
-8.67
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-37.06%
Return on Equity (ttm)
--
Revenue (ttm)
148.98k
Net Income Avi to Common (ttm)
-4.56M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
749.25k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.45M
Company Insights: KNE.V
KNE.V does not have Company Insights